Table 2.
Covid-19 Case and Death Rates among Fully Vaccinated Persons by Time since Vaccination for 15 U.S. Jurisdictions, from August 1 to September 4, 2021
| Characteristic | January to February | March to April | May to June | July | ||||
|---|---|---|---|---|---|---|---|---|
| No. of Covid-19 cases/deaths | Covid-19 case/death rate per 100,000 person-wk* | No. of Covid-19 cases/deaths | Covid-19 case/death rate per 100,000 person-wk* | No. of Covid-19 cases/deaths | Covid-19 case/death rate per 100,000 person-wk* | No. of Covid-19 cases/deaths | Covid-19 case/death rate per 100,000 person-wk* | |
| 15 jurisdictions | ||||||||
| Overall cases | 67,954 | 168.8 (167.5–170.1) | 145,059 | 123.5 (122.8–124.1) | 54,909 | 83.6 (82.9–84.3) | 7070 | 63.1 (61.6–64.6) |
| Age — yr | ||||||||
| 12–17 | 50 | 164.5 (124.7–217.1) | 1429 | 139.0 (132.0–146.4) | 5060 | 68.6 (66.7–70.5) | 1074 | 47.7 (44.9–50.6) |
| 18–49 | 25,621 | 219.8 (217.2–222.6) | 64,217 | 156.5 (155.3–157.7) | 34,157 | 91.4 (90.5–92.4) | 4036 | 68.0 (65.9–70.1) |
| 50–64 | 12,703 | 166.8 (163.9–169.7) | 43,745 | 118.1 (117.0–119.2) | 11,478 | 76.0 (74.6–77.4) | 1359 | 64.8 (61.5–68.4) |
| 65–79 | 19,989 | 134.8 (132.9–136.6) | 28,760 | 93.2 (92.1–94.3) | 3311 | 69.5 (67.2–71.9) | 461 | 61.3 (56–67.2) |
| ≥80 | 9591 | 156.7 (153.6–159.9) | 6908 | 91.8 (89.7–94) | 903 | 84.5 (79.1–90.2) | 140 | 81.8 (69.3–96.6) |
| Vaccine product | ||||||||
| BNT162b2 (Pfizer-BioNTech) | 44,898 | 201.6 (199.7–203.4) | 83,247 | 139.7 (138.8–140.7) | 34,072 | 92.2 (91.3–93.2) | 4186 | 58.0 (56.3–59.8) |
| mRNA-1273 (Moderna) | 23,056 | 128.2 (126.6–129.9) | 39,271 | 85.3 (84.5–86.2) | 14,338 | 61.4 (60.4–62.4) | 1114 | 40.5 (38.2–42.9) |
| Ad26.COV2.S (Janssen–Johnson & Johnson) | NA | 22,541 | 189.7 (187.3–192.2) | 6499 | 120.6 (117.7–123.6) | 1770 | 142.6 (136.1–149.4) | |
| Vaccine product and recipient age — yr | ||||||||
| BNT162b2 | ||||||||
| 12–17 | 50 | 164.5 (124.7–217.1) | 1429 | 139.0 (132.0–146.4) | 5060 | 68.6 (66.7–70.5) | 1074 | 47.7 (44.9–50.6) |
| 18–49 | 16,817 | 254.8 (251.0–258.7) | 38,013 | 165.2 (163.6–166.9) | 20,899 | 104.4 (103–105.8) | 2233 | 66.0 (63.3–68.8) |
| 50–64 | 8347 | 202.4 (198.1–206.8) | 24,896 | 129.2 (127.6–130.9) | 6135 | 86.5 (84.4–88.7) | 620 | 55.4 (51.2–59.9) |
| 65–79 | 13,035 | 162.5 (159.7–165.3) | 15,433 | 115.6 (113.8–117.4) | 1552 | 76.4 (72.7–80.3) | 197 | 52.1 (45.3–59.9) |
| ≥80 | 6649 | 190.1 (185.6–194.7) | 3476 | 118.6 (114.7–122.6) | 426 | 99.3 (90.3–109.1) | 62 | 76.5 (59.7–98.2) |
| mRNA-1273 | ||||||||
| 18–49 | 8804 | 174.2 (170.6–177.9) | 14,168 | 114.1 (112.2–116.0) | 9410 | 67.1 (65.7–68.4) | 699 | 41.2 (38.3–44.4) |
| 50–64 | 4356 | 124.7 (121.0–128.4) | 11,311 | 82.5 (81.0–84.0) | 3500 | 53.1 (51.4–54.9) | 265 | 37.4 (33.2–42.2) |
| 65–79 | 6954 | 102.1 (99.7–104.5) | 10,937 | 69.4 (68.1–70.7) | 1123 | 50.5 (47.6–53.5) | 109 | 38.7 (32.1–46.7) |
| ≥80 | 2942 | 112.2 (108.2–116.3) | 2855 | 68.9 (66.5–71.5) | 305 | 60.4 (54.0–67.6) | 41 | 60.2 (44.3–81.8) |
| Ad26.COV2.S | ||||||||
| 18–49 | NA | 12,036 | 214.1 (210.3–218) | 3848 | 116.1 (112.5–119.8) | 1104 | 128.7 (121.3–136.5) | |
| 50–64 | NA | 7538 | 185.5 (181.4–189.8) | 1843 | 128.6 (122.8–134.6) | 474 | 175.7 (160.6–192.3) | |
| 65–79 | NA | 2390 | 137.0 (131.6–142.6) | 636 | 125.4 (116.0–135.5) | 155 | 168.9 (144.3–197.7) | |
| ≥80 | NA | 577 | 127.8 (117.8–138.7) | 172 | 127.5 (109.8–148) | 37 | 167.9 (121.6–231.7) | |
| Region† | ||||||||
| South | 34,973 | 221.4 (219.1–223.8) | 74,808 | 178.9 (177.6–180.2) | 28,941 | 128.9 (127.4–130.4) | 4266 | 94.3 (91.5–97.2) |
| West | 9138 | 164.7 (161.3–168.1) | 16,396 | 105.3 (103.7–106.9) | 5562 | 76.5 (74.5–78.5) | 788 | 55.8 (52.0–59.8) |
| Northeast | 9208 | 104.9 (102.8–107) | 25,758 | 80.9 (79.9–81.9) | 10,602 | 48.5 (47.6–49.5) | 987 | 30.1 (28.2–32.0) |
| Midwest | 14,635 | 144.4 (142.1–146.8) | 28,097 | 99.4 (98.3–100.6) | 9804 | 69.5 (68.1–70.9) | 1029 | 51.8 (48.7–55.1) |
| 14 jurisdictions | ||||||||
| Overall deaths | 1512 | 4.00 (3.80–4.20) | 1779 | 1.62 (1.55–1.7) | 376 | 0.6 (0.54–0.67) | 54 | 0.5 (0.38–0.66) |
| Age — yr | ||||||||
| 12–17 | 0 | 0‡ | 1 | 0.11 (0.01–0.75)‡ | 0 | 0‡ | 0 | 0‡ |
| 18–49 | 9 | 0.08 (0.04–0.16)‡ | 44 | 0.11 (0.09–0.15) | 17 | 0.05 (0.03–0.08) | 5 | 0.09 (0.04–0.21)‡ |
| 50–64 | 58 | 0.81 (0.63–1.05) | 286 | 0.82 (0.73–0.92) | 90 | 0.63 (0.51–0.78) | 11 | 0.55 (0.3–0.99)‡ |
| 65–79 | 462 | 3.29 (3.00–3.60) | 754 | 2.62 (2.44–2.82) | 151 | 3.3 (2.81–3.87) | 26 | 3.59 (2.44–5.27) |
| ≥80 | 983 | 17.06 (16.02–18.16) | 694 | 9.96 (9.25–10.73) | 118 | 11.46 (9.57–13.72) | 12 | 7.28 (4.13–12.82)‡ |
| Vaccine product | ||||||||
| BNT162b2 | 1135 | 5.49 (5.18–5.82) | 869 | 1.55 (1.45–1.66) | 148 | 0.42 (0.36–0.49) | 15 | 0.22 (0.13–0.36) |
| mRNA-1273 | 377 | 2.2 (1.99–2.43) | 600 | 1.4 (1.3–1.52) | 127 | 0.57 (0.48–0.68) | 9 | 0.34 (0.18–0.65)‡ |
| Ad26.COV2.S | NA | 310 | 2.8 (2.5–3.13) | 101 | 1.97 (1.62–2.39) | 30 | 2.52 (1.76–3.6) | |
| Vaccine product and recipient age — yr | ||||||||
| BNT162b2 | ||||||||
| 12–17 | 0 | 0‡ | 1 | 0.11 (0.01–0.75)‡ | 0 | 0‡ | 0 | 0‡ |
| 18–49 | 5 | 0.08 (0.03–0.20)‡ | 20 | 0.09 (0.06–0.14) | 6 | 0.03 (0.01–0.07)‡ | 2 | 0.06 (0.02–0.25)‡ |
| 50–64 | 38 | 0.99 (0.72–1.36) | 124 | 0.68 (0.57–0.81) | 34 | 0.51 (0.36–0.71) | 6 | 0.56 (0.25–1.25)‡ |
| 65–79 | 318 | 4.26 (3.82–4.76) | 378 | 3.03 (2.74–3.35) | 59 | 3.02 (2.34–3.90) | 5 | 1.37 (0.57–3.3)‡ |
| ≥80 | 774 | 23.55 (21.94–25.26) | 346 | 12.72 (11.45–14.13) | 49 | 11.89 (8.98–15.73) | 2 | 2.56 (0.64–10.26)‡ |
| mRNA-1273 | ||||||||
| 18–49 | 4 | 0.08 (0.03–0.22)‡ | 10 | 0.09 (0.05–0.16)‡ | 10 | 0.07 (0.04–0.14)‡ | 0 | 0‡ |
| 50–64 | 20 | 0.60 (0.39–0.94) | 70 | 0.54 (0.43–0.69) | 28 | 0.45 (0.31–0.66) | 0 | 0‡ |
| 65–79 | 144 | 2.19 (1.86–2.57) | 252 | 1.73 (1.53–1.95) | 47 | 2.19 (1.65–2.91) | 6 | 2.20 (0.99–4.89)‡ |
| ≥80 | 209 | 8.44 (7.37–9.67) | 268 | 7.03 (6.24–7.93) | 42 | 8.60 (6.36–11.64) | 3 | 4.55 (1.47–14.11)‡ |
| Ad26.COV2.S | ||||||||
| 18–49 | NA | 14 | 0.27 (0.16–0.45)‡ | 1 | 0.03 (0–0.22)‡ | 3 | 0.36 (0.12–1.12)‡ | |
| 50–64 | NA | 92 | 2.44 (1.99–3.00) | 28 | 2.08 (1.43–3.01) | 5 | 1.96 (0.82–4.71)‡ | |
| 65–79 | NA | 124 | 7.38 (6.19–8.80) | 45 | 9.33 (6.97–12.5) | 15 | 17.24 (10.39–28.59) | |
| ≥80 | NA | 80 | 18.29 (14.69–22.77) | 27 | 20.9 (14.33–30.48) | 7 | 33.37 (15.91–69.99)‡ | |
| Region | ||||||||
| South | 1142 | 7.23 (6.82–7.66) | 1285 | 3.07 (2.91–3.25) | 280 | 1.25 (1.11–1.4) | 44 | 0.97 (0.72–1.31) |
| West | 102 | 1.84 (1.51–2.23) | 130 | 0.83 (0.7–0.99) | 31 | 0.43 (0.3–0.61) | 3 | 0.21 (0.07–0.66)‡ |
| Northeast | 92 | 1.05 (0.85–1.29) | 164 | 0.51 (0.44–0.60) | 34 | 0.16 (0.11–0.22) | 4 | 0.12 (0.05–0.32)‡ |
| Midwest | 176 | 2.28 (1.97–2.65) | 200 | 0.97 (0.84–1.11) | 31 | 0.28 (0.20–0.40) | 3 | 0.20 (0.06–0.61)‡ |
*
Rates for counts less than 15 may be unstable and should be interpreted with caution. NA denotes not applicable.
†
Regions comprise the following jurisdictions: South (Arkansas, Georgia, Florida, and Tennessee), West (Arizona, Idaho, New Mexico, and Utah), Northeast (Massachusetts, New Jersey, and New York City), and Midwest (Indiana, Michigan, Nebraska, and Wisconsin). Wisconsin did not contribute death data due to lack of linkage between vital records and COVID-19 case surveillance.
‡
Rates were calculated using person-weeks as denominator, and 95% confidence intervals provided in parentheses. The widths of the intervals have not been adjusted for multiplicity and any of the inferences drawn may not be reproducible.